Sutro Biopharma (STRO) Assets Average (2018 - 2026)

Sutro Biopharma has reported Assets Average for 8 years, with the latest figure at $191.7 million in Q4 2025.

• Quarterly Assets Average fell 54.29% year-over-year to $191.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $191.7 million (down 54.29% YoY) and the FY2025 annual result came in at $280.5 million, down 34.61% from the prior year.
• Assets Average fell to $191.7 million in Q4 2025 per STRO's latest filing, from $236.0 million in the prior quarter.
• Over five years, Assets Average peaked at $470.4 million in Q3 2024 and troughed at $191.7 million in Q4 2025.
• A 5-year average of $373.1 million and a median of $379.4 million in 2021 frame the typical range for Assets Average.
• The sharpest annual moves came in 2021 and 2025: Assets Average surged 142.6% in 2021, then plunged 54.29% in 2025.
• Over 5 years, Assets Average stood at $356.4 million in 2021, then rose by 13.29% to $403.8 million in 2022, then grew by 11.74% to $451.2 million in 2023, then dropped by 7.03% to $419.5 million in 2024, then slumped by 54.29% to $191.7 million in 2025.
• According to Business Quant data, Assets Average over the past three periods registered $191.7 million, $236.0 million, and $291.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.